 life expect patient chronic nonleukem myeloprolif disord studi frame current therapeut possibl impact chronic nonleukem myeloprolif disord surviv surviv data patient polycythemia vera essenti thrombocythemia idiopath myelofibrosi spanish institut actuari surviv probabl group patient age-match sex-match control popul surviv patient polycythemia vera essenti thrombocythemia control popul surviv patient idiopath myelofibrosi respect control popul term surviv current therapeut procedur satisfactori patient polycythemia vera essenti thrombocythemia hand due poor surviv patient idiopath myelofibrosi new therapeut approach condit